Chris O’Brien Lifehouse

Institution (Nonprofit)

Homepage ROR

Also Known As

Chris O’Brien Lifehouse

2.4K

Publications

131.5K

Citations

Authors

421

Concepts

About

Chris O’Brien Lifehouse is a nonprofit institution in Camperdown, Australia known for medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	28	129	6.2K
2	Engineering	17	59	9.4K
3	Arts	2	2	66
4	Education	2	2	47
5	Business	1	2	104

Chris O’Brien Lifehouse

2.4K

Publications

131.5K

Citations

Page 1

	Year	Citations
Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer Leena Gandhi, Delvys Rodríguez‐Abreu, Shirish M. Gadgeel, New England Journal of Medicine	2018	6.4K
Pembrolizumab versus Ipilimumab in Advanced Melanoma Caroline Robert, Jacob Schachter, Georgina V. Long, New England Journal of Medicine	2015	5.7K
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation Caroline Robert, Georgina V. Long, Benjamin Brady, New England Journal of Medicine	2014	5.3K
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study Aurélien Marabelle, Marwan Fakih, Juanita Lopez, The Lancet Oncology	2020	2.4K
A single-cell and spatially resolved atlas of human breast cancers Sunny Z. Wu, Ghamdan Al‐Eryani, Daniel Roden, Nature Genetics Tumor BiologyBreast OncologyEngineeringTumor HeterogeneityMedicine	2021	1.6K
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) Jacob Schachter, Antoni Ribas, Georgina V. Long, The Lancet Open-label Phase 3MedicineMelanomaImmune Checkpoint InhibitorDermatology	2017	1.2K
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial Keunchil Park, Eng-Huat Tan, Kenneth J. O’Byrne, The Lancet Oncology OncologyPhase 2BPathologyBronchial NeoplasmAfatinib Versus Gefitinib	2016	1.1K
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer Shirish M. Gadgeel, Delvys Rodríguez‐Abreu, Giovanna Speranza, Journal of Clinical Oncology	2020	1.1K
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study Caroline Robert, Antoni Ribas, Jacob Schachter, The Lancet Oncology MedicineMelanomaImmunologyTumor ImmunityImmune Checkpoint Inhibitor	2019	1.1K

Page 1